IL17A and psoriasis: Finally, a promising approach may be the use of specific monoclonal antibodies directed against molecules involved in autoimmunity: in a case series reported by Frustaci et al., the addition of secukinumab, an interleukin-17A inhibitor, to standard immunosuppressive therapy was associated with complete ventricular function recovery in patients with psoriasis-relate myocarditis [90].